Medication info
Sitagliptin and Metformin XR Tablet 50/1000mg (Sitagliptin, Metformin)

Sitagliptin and Metformin XR Tablet 50/1000mg (Sitagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletSitagliptin Phosphate Hydrate›64.25mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Green, biconvex, oval-shaped extended-release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201505032 · Approved 2015.07.23 · Insurance code 643507380

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For this 100/1000 mg extended-release tablet, take 1 tablet once daily. Patients taking this 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. Patients receiving metformin: For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this 50/1000 mg extended-release tablet once daily. Patients who do not achieve adequate glycemic control with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes. It is used as an adjunct to diet and exercise and works effectively to manage blood sugar levels by the combined actions of sitagliptin and metformin. This contributes to reducing blood sugar fluctuations and improving diabetes symptoms.

How to take

Adult dose

For antidiabetic therapy, determine the dose of this medicine based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this medicine with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. For this 100/1000 mg extended-release tablet, take 1 tablet once daily. Patients taking this 50/500 mg extended-release tablet or 50/1000 mg extended-release tablet should take 2 tablets together once daily. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control is not achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. Patients receiving metformin: For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this medicine is sitagliptin 100 mg and the current metformin dose. Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start with their current doses of sitagliptin and metformin. Patients taking immediate-release metformin at a current dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this 50/1000 mg extended-release tablet once daily. Patients who do not achieve adequate glycemic control with concomitant metformin and sulfonylurea, metformin and insulin, or metformin and thiazolidinedione therapy: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin. No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication contains both sitagliptin and metformin and is primarily used for blood sugar control in patients with type 2 diabetes. Firstly, the sitagliptin component can cause rare but serious allergic reactions. If symptoms such as skin rash, hives, or difficulty breathing occur, the medication should be discontinued immediately, and a doctor should be consulted. Additionally, sitagliptin can cause acute pancreatitis, which is inflammation of the pancreas, so if there are symptoms like abdominal pain or vomiting, medical personnel should be notified immediately. The metformin component can cause a rare complication called lactic acidosis, which is a condition where lactic acid builds up excessively in the blood and can be life-threatening if severe. This condition can start with nonspecific symptoms such as vomiting, abdominal pain, difficulty breathing, muscle pain, and fatigue, so caution is needed. Patients with impaired kidney function, severe infections, dehydration, heart failure, or liver disease may be at risk when using this medication, and it should not be administered. The use of iodine-containing contrast agents should require a temporary discontinuation of this medication before and after tests, and it should be resumed only after confirming normal kidney function post-examination. It is advisable not to use this medication during pregnancy or lactation due to the lack of established safety, and it is also not recommended for children under 18 years of age. Regular kidney function tests and blood tests should be conducted during the use of this medication, and vitamin B12 levels should also be checked periodically. Furthermore, caution should be taken as the risk of hypoglycemia may increase when used with other blood sugar-lowering agents or insulin. Dosage adjustments should be made according to a doctor's guidance when needed. Excessive alcohol consumption should be avoided while taking this medication as it can increase the risk of lactic acidosis. In the event of surgery, severe infections, or dehydration symptoms, it is safer to temporarily discontinue the medication and resume after recovery. Lastly, it is important to consult medical personnel immediately if any unusual symptoms occur during the use of this medication to receive appropriate care.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, severe and disability-associated arthralgia, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, rash, urticaria, cutaneous vasculitis, elevated liver enzymes, acute renal failure, hypoglycemia, peripheral edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is best to store it at room temperature between 1°C and 30°C. This way, the medication's efficacy can be maintained for a long time.

Appearance and packaging

Appearance

Green, biconvex, oval-shaped extended-release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.